Menarini Biomarkers Singapore

History

Menarini Biomarkers Singapore (MBS) was created in 2014 by Menarini Asia-Pacific and is fully owned by the Menarini Group, the world’s largest Italian biopharmaceutical company with annual revenue exceeding 3.6 billion euros (2017). Founded in 1886, Menarini has grown to encompass over 17,000 employees working in 140 countries today and possess an extensive brands portfolio consisting of products in the key therapeutic areas of aesthetics, allergy/respiratory, cardio-metabolic, consumer healthcare, dermatology, gastroenterology, men’s health and pain management.

Mission

Menarini Biomarkers Singapore’s mission is to identify, develop and validate new biomarkers on circulating human cells for applications in diagnostics.

Many novel biomarkers will be identified using single cells analysis in the coming years. These discoveries will drive precision medicine, the new frontier in disease prediction and disease control. From liquid biopsies, circulating cells such as CFC (circulating fetal cells), CTC (circulating tumor cells) and PIC (pathogenic immune cells) will be captured by specific antibodies developed against novel targets, conjugated to FerroFluid (Cell Search Technology) and further selected and analysed using the DEPArray platform. Together with Menarini Silicon Biosystems (MSB), MBS aims to recover and select the rarest cell types from any type of tissues or liquid biopsies. The identified novel biomarkers will provide new tools and actionable insights for clinicians to track disease progression and measure real-time responses to therapies.

For more information, please visit the Menarini Biomarkers Singapore.